Neogen Corp (NEOG) stock
NEOGNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 7, 2026Score 7/3049% above fair value
$10.90+0.02 (+0.18%)
Close on Nov 17, 2026Market cap $2.38BP/E –Yield –
Neogen r&d expenses
Research and development expenses are spending on new products and technology.
Neogen's R&D Expenses for the twelve months ending Aug 31, 2026 was $19.76M, down 5.9% year over year. For fiscal 2026 it was $18.40M, down 12.8% from the year before. Over ten years it grew 6.4% a year on average. The highest annual figure on record is $26.04M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | May 31, 2026 | $18.40M | -12.8% |
| FY2025 | May 31, 2025 | $21.10M | -6.2% |
| FY2024 | May 31, 2024 | $22.50M | -13.6% |
| FY2023 | May 31, 2023 | $26.04M | +52.7% |
| FY2022 | May 31, 2022 | $17.05M | +4.9% |
| FY2021 | May 31, 2021 | $16.25M | +10.1% |
| FY2020 | May 31, 2020 | $14.75M | +15.2% |
| FY2019 | May 31, 2019 | $12.81M | +18.0% |
| FY2018 | May 31, 2018 | $10.86M | +4.5% |
| FY2017 | May 31, 2017 | $10.39M | +5.0% |
| FY2016 | May 31, 2016 | $9.89M | +3.3% |
| FY2015 | May 31, 2015 | $9.58M | +15.0% |
| FY2014 | May 31, 2014 | $8.33M | +7.0% |
| FY2013 | May 31, 2013 | $7.78M | +17.3% |
| FY2012 | May 31, 2012 | $6.64M | -2.8% |
| FY2011 | May 31, 2011 | $6.83M | +9.1% |
| FY2010 | May 31, 2010 | $6.26M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Aug 31, 2026 | $6.50M | +27.5% |
| Q4 FY2026CQ2 2026 | May 31, 2026 | $4.90M | -22.2% |
| Q3 FY2026CQ1 2026 | Feb 28, 2026 | $3.80M | -15.6% |
| Q2 FY2026CQ4 2025 | Nov 30, 2025 | $4.56M | -10.7% |
| Q1 FY2026CQ3 2025 | Aug 31, 2025 | $5.10M | -1.9% |
| Q4 FY2025CQ2 2025 | May 31, 2025 | $6.30M | +21.9% |
| Q3 FY2025CQ1 2025 | Feb 28, 2025 | $4.50M | -7.3% |
| Q2 FY2025CQ4 2024 | Nov 30, 2024 | $5.11M | -11.3% |
| Q1 FY2025CQ3 2024 | Aug 31, 2024 | $5.20M | -22.7% |
| Q4 FY2024CQ2 2024 | May 31, 2024 | $5.17M | -26.7% |
| Q3 FY2024CQ1 2024 | Feb 29, 2024 | $4.85M | -33.1% |
| Q2 FY2024CQ4 2023 | Nov 30, 2023 | $5.76M | -15.9% |
| Q1 FY2024CQ3 2023 | Aug 31, 2023 | $6.72M | +37.7% |
| Q4 FY2023CQ2 2023 | May 31, 2023 | $7.05M | +84.1% |
| Q3 FY2023CQ1 2023 | Feb 28, 2023 | $7.26M | +59.1% |
| Q2 FY2023CQ4 2022 | Nov 30, 2022 | $6.85M | +58.0% |
| Q1 FY2023CQ3 2022 | Aug 31, 2022 | $4.88M | +12.9% |
| Q4 FY2022CQ2 2022 | May 31, 2022 | $3.83M | -6.0% |
| Q3 FY2022CQ1 2022 | Feb 28, 2022 | $4.56M | +7.7% |
| Q2 FY2022CQ4 2021 | Nov 30, 2021 | $4.33M | +6.8% |
| Q1 FY2022CQ3 2021 | Aug 31, 2021 | $4.33M | +11.5% |
| Q4 FY2021CQ2 2021 | May 31, 2021 | $4.08M | +17.9% |
| Q3 FY2021CQ1 2021 | Feb 28, 2021 | $4.24M | +10.8% |
| Q2 FY2021CQ4 2020 | Nov 30, 2020 | $4.06M | +7.3% |
| Q1 FY2021CQ3 2020 | Aug 31, 2020 | $3.88M | +5.2% |
| Q4 FY2020CQ2 2020 | May 31, 2020 | $3.46M | -3.1% |
| Q3 FY2020CQ1 2020 | Feb 29, 2020 | $3.82M | +17.7% |
| Q2 FY2020CQ4 2019 | Nov 30, 2019 | $3.78M | +19.4% |
| Q1 FY2020CQ3 2019 | Aug 31, 2019 | $3.69M | +30.8% |
| Q4 FY2019CQ2 2019 | May 31, 2019 | $3.57M | +82.7% |
| Q3 FY2019CQ1 2019 | Feb 28, 2019 | $3.25M | +14.6% |
| Q2 FY2019CQ4 2018 | Nov 30, 2018 | $3.17M | +6.7% |
| Q1 FY2019CQ3 2018 | Aug 31, 2018 | $2.82M | -9.0% |
| Q4 FY2018CQ2 2018 | May 31, 2018 | $1.95M | -15.0% |
| Q3 FY2018CQ1 2018 | Feb 28, 2018 | $2.84M | +7.4% |
| Q2 FY2018CQ4 2017 | Nov 30, 2017 | $2.97M | +7.2% |
| Q1 FY2018CQ3 2017 | Aug 31, 2017 | $3.10M | – |
| Q4 FY2017CQ2 2017 | May 31, 2017 | $2.30M | – |
| Q3 FY2017CQ1 2017 | Feb 28, 2017 | $2.64M | – |
| Q2 FY2017CQ4 2016 | Nov 30, 2016 | $2.77M | – |
See a number that looks wrong?